Cargando…

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab

Listeria monocytogenes is a gram-positive bacterium that causes listeriosis. Brain abscess is a very uncommon manifestation of listeriosis and has not been reported to be associated with adalimumab (humira), one of the approved medications for treating Crohn's disease. A 45-year-old female with...

Descripción completa

Detalles Bibliográficos
Autores principales: Atsawarungruangkit, Amporn, Dominguez, Fernando, Borda, Gustavo, Mavrogiorgos, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731156/
https://www.ncbi.nlm.nih.gov/pubmed/29282389
http://dx.doi.org/10.1159/000481165
_version_ 1783286474428383232
author Atsawarungruangkit, Amporn
Dominguez, Fernando
Borda, Gustavo
Mavrogiorgos, Nikolaos
author_facet Atsawarungruangkit, Amporn
Dominguez, Fernando
Borda, Gustavo
Mavrogiorgos, Nikolaos
author_sort Atsawarungruangkit, Amporn
collection PubMed
description Listeria monocytogenes is a gram-positive bacterium that causes listeriosis. Brain abscess is a very uncommon manifestation of listeriosis and has not been reported to be associated with adalimumab (humira), one of the approved medications for treating Crohn's disease. A 45-year-old female with Crohn's disease presented with sudden onset of fever, headache, nausea, vomiting, and altered mental status for 1 day. She was on prednisone and 6-mercaptopurine. She had started taking adalimumab 17 days prior to admission. She had signs of toxicity, confusion, and nuchal rigidity, but showed neither central nervous system deficits nor focal deficits. The laboratory results revealed Gram-positive coccobacillus, positive blood and cerebrospinal fluid culture for Listeria monocytogenes, and a 5 × 5 mm ring-enhancing lesion of brain abscess on MRI. After holding off 6-mercaptopurine and adalimumab, her mental status improved on the next day. Finally, she was discharged on day 7 of hospitalization with ampicillin 2 g intravenously every 4 h for a total of 2 weeks. Two weeks later, the follow-up MRI showed a 2-mm area of residual enhancement in the left temporal lobe at the site of the previous brain abscess. Adalimumab, as a tumor necrosis factor (TNF)-alpha inhibitor, carries a risk of triggering opportunistic infection, such as listeriosis. With an altered mental status or neurological signs in patients receiving TNF-alpha antagonizing agent, physicians should suspect bacterial infection in the central nervous system and promptly initiate treatment for brain abscess if needed.
format Online
Article
Text
id pubmed-5731156
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-57311562017-12-27 Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab Atsawarungruangkit, Amporn Dominguez, Fernando Borda, Gustavo Mavrogiorgos, Nikolaos Case Rep Gastroenterol Single Case Listeria monocytogenes is a gram-positive bacterium that causes listeriosis. Brain abscess is a very uncommon manifestation of listeriosis and has not been reported to be associated with adalimumab (humira), one of the approved medications for treating Crohn's disease. A 45-year-old female with Crohn's disease presented with sudden onset of fever, headache, nausea, vomiting, and altered mental status for 1 day. She was on prednisone and 6-mercaptopurine. She had started taking adalimumab 17 days prior to admission. She had signs of toxicity, confusion, and nuchal rigidity, but showed neither central nervous system deficits nor focal deficits. The laboratory results revealed Gram-positive coccobacillus, positive blood and cerebrospinal fluid culture for Listeria monocytogenes, and a 5 × 5 mm ring-enhancing lesion of brain abscess on MRI. After holding off 6-mercaptopurine and adalimumab, her mental status improved on the next day. Finally, she was discharged on day 7 of hospitalization with ampicillin 2 g intravenously every 4 h for a total of 2 weeks. Two weeks later, the follow-up MRI showed a 2-mm area of residual enhancement in the left temporal lobe at the site of the previous brain abscess. Adalimumab, as a tumor necrosis factor (TNF)-alpha inhibitor, carries a risk of triggering opportunistic infection, such as listeriosis. With an altered mental status or neurological signs in patients receiving TNF-alpha antagonizing agent, physicians should suspect bacterial infection in the central nervous system and promptly initiate treatment for brain abscess if needed. S. Karger AG 2017-11-09 /pmc/articles/PMC5731156/ /pubmed/29282389 http://dx.doi.org/10.1159/000481165 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Atsawarungruangkit, Amporn
Dominguez, Fernando
Borda, Gustavo
Mavrogiorgos, Nikolaos
Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title_full Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title_fullStr Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title_full_unstemmed Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title_short Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
title_sort listeria monocytogenes brain abscess in crohn's disease treated with adalimumab
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731156/
https://www.ncbi.nlm.nih.gov/pubmed/29282389
http://dx.doi.org/10.1159/000481165
work_keys_str_mv AT atsawarungruangkitamporn listeriamonocytogenesbrainabscessincrohnsdiseasetreatedwithadalimumab
AT dominguezfernando listeriamonocytogenesbrainabscessincrohnsdiseasetreatedwithadalimumab
AT bordagustavo listeriamonocytogenesbrainabscessincrohnsdiseasetreatedwithadalimumab
AT mavrogiorgosnikolaos listeriamonocytogenesbrainabscessincrohnsdiseasetreatedwithadalimumab